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or the TAXUS-IV Investigators
ew York, Roslyn, and Manhasset, New York; Cleveland, Ohio; Houston, Texas; Lincoln, Nebraska;
nd Natick, Massachusetts
OBJECTIVES We sought to examine the efficacy of paclitaxel-eluting stent implantation in the left anterior
descending coronary artery (LAD).
BACKGROUND Restenosis and recurrent cardiac events after percutaneous intervention are more common for
lesions in the LAD than other native coronary arteries, and often necessitate bypass surgery.
Drug-eluting stents may improve the long-term prognosis of this high-risk group.
METHODS In the TAXUS-IV trial, 1,314 patients with single de novo coronary lesions were assigned to
implantation of the slow-release, polymer-based, paclitaxel-eluting TAXUS stent or an
identical bare-metal stent; 536 (41%) randomized patients had LAD lesions.
RESULTS Baseline characteristics of patients with LAD lesions were well-matched between the
randomized groups. Late lumen loss at nine months after paclitaxel-eluting and control stent
implantation were 0.28  0.51 mm and 0.54  0.57 mm, respectively (p  0.0004), and
binary restenosis rates were 11.3% and 26.9%, respectively (p  0.004). At one year, major
adverse cardiac events (MACE) occurred in 13.5% of TAXUS-treated patients versus 21.2%
treated with the control stent (p 0.01). The need for bypass surgery at one year was reduced
among patients randomized to the TAXUS stent (2.6% vs. 6.3%, p  0.02). In the proximal
LAD subgroup (n  126), the one-year target vessel revascularization rate was 7.9% with the
TAXUS stent and 18.6% with the bare-metal stent (p  0.009).
CONCLUSIONS Compared to bare-metal stents, implantation of polymer-based, paclitaxel-eluting stents in
LAD lesions is safe, and reduces angiographic restenosis and MACE one year. Notably, the
need for bypass graft surgery due to restenosis is reduced after TAXUS stent implantation in
LAD lesions. (J Am Coll Cardiol 2005;45:1186–92) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.077Cardiology Foundation
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The implantation of drug-eluting coronary stents signifi-
antly reduces angiographic restenosis and recurrent cardiac
vents compared to bare-metal stents, which are, in turn,
uperior to balloon angioplasty alone (1–5). One of the
redictors of angiographic restenosis after balloon angio-
lasty and bare-metal stent implantation is the location of
he target lesion in the left anterior descending coronary
rtery (LAD) (5–11). Numerous studies have investigated
he outcomes of percutaneous coronary intervention (PCI)
nd bypass surgery in patients with LAD stenosis (12–20).
n most of these studies, the long-term rates of survival free
rom re-infarction have been similar after the two revascu-
arization techniques; the biggest differences noted have
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anhasset, New York; St. Luke’s Episcopal Hospital, Houston, Texas; ¶Nebraska
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ccepted October 25, 2004.een a greater rate of recurrent target lesion revasculariza-
ion (TLR) and target vessel revascularization (TVR) after
CI compared to surgery. Moreover, a recently published
eport found LAD bypass grafting to be the best predictor
f event-free survival at three years after bypass graft surgery
20), underlining the importance of sustained LAD patency.
Importantly, drug-eluting stents were used in none of the
bove-mentioned comparative studies. The specific results
ith these bioactive devices in the LAD, and their potential
mpact in improving long-term outcomes after PCI, have
ot been examined. The present study represents a pre-
pecified, secondary analysis from the TAXUS-IV trial (1),
xamining early and late outcomes of patients randomized
o the slow-release, polymer-based, paclitaxel-eluting stent
o PCI with bare-metal stents as a function of epicardial
arget lesion location.
ETHODS
AXUS-IV study design. The study population, design,
nd overall conduct of the TAXUS-IV randomized trial
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April 19, 2005:1186–92 Paclitaxel-Eluting Stent in LAD Stenosesave been published in detail elsewhere (1). In brief, the
AXUS study enrolled patients with stable or unstable
ngina or provokable ischemia undergoing PCI of a single
e novo lesion in a native coronary artery. Angiographic
nclusion required the presence of a single, non-ostial, target
esion with visually estimated reference vessel diameter2.5
o 3.75 mm and lesion length 10 to 28 mm coverable by
single study stent. Telephone randomization was per-
ormed before pre-dilatation, stratified by the presence of
edically treated diabetes and vessel size. Patients were
qually assigned in a double-blind fashion using random
erial numbers to treatment with either the slow rate-
elease, polymer-based, paclitaxel-eluting EXPRESS stent
the TAXUS stent, Boston Scientific Corp., Natick, Mas-
achusetts) or a visually indistinguishable bare-metal
XPRESS stent.
Patients were pretreated with aspirin, and a 300-mg oral
oading dose of clopidogrel was recommended. Unfraction-
ted heparin was administered per standard practice, and
lycoprotein IIb/IIIa inhibitor use was at the operator’s
iscretion. After mandatory pre-dilatation, an appropriate-
ized stent (approximately 2 to 4 mm longer than the lesion
ith a stent-to-distal reference vessel diameter ratio of 1 to
.1:1) was implanted at 12 atm. Stents were available in
engths of 16, 24, and 32 mm, and in diameters of 2.5, 3.0,
nd 3.5 mm. Additional study stents were permitted for
dge dissections greater than or equal to type B or otherwise
uboptimal results, and post-dilatation was at the operator’s
iscretion.
After PCI, patients were maintained on aspirin 325 mg
aily indefinitely and clopidogrel 75 mg daily for at least six
onths. Clinical follow-up was scheduled at one, four, and
ine months, and yearly thereafter for five years. Angio-
raphic follow-up was pre-specified in a subgroup of 732
atients at nine months.
Details of trial management have been previously re-
orted, as have the study end points (1). All major adverse
ardiac events (MACE) were adjudicated by an indepen-
ent committee blinded to treatment allocation after review
f original source documentation. Independent core angio-
raphic laboratory analysis was performed blinded to clinical
Abbreviations and Acronyms
CI  confidence interval
HR  hazard ratio
LAD  left anterior descending coronary artery
LCX  left circumflex coronary artery
MACE  major adverse cardiac event
OR  odds ratio
PCI  percutaneous coronary intervention
RCA  right coronary artery
TLR  target lesion revascularization
TVR  target vessel revascularizationutcomes using validated quantitative methods (21,22). oeasures were reported separately within the stent, within
mm proximal and distal to each edge, and over the entire
nalysis segment.
tatistical methods. Categorical variables were compared
y the Fisher exact test for two-way comparisons or the
hi-square test for trend for three-way comparisons. Con-
inuous variables are presented as mean  1 SD or median
ith interquartile ranges, and were compared by the
ilcoxon two-sample test. The influence of baseline vari-
bles on one-year categorical end points was evaluated with
ogistic regression. Survival estimates were created using
aplan-Meier methodology, and compared with the log-
ank test. Independent determinates of event-free survival
ere identified with Cox proportional hazards regression.
andidate variables for multivariate analyses included: ran-
omization arm, age, female gender, current smoker, any
iabetes, LAD location, previous myocardial infarction,
ypertension, hyperlipidemia, left ventricular ejection frac-
ion, unstable angina, bailout stent used, non-study stents
sed, total stent length, maximum device pressure, maxi-
um device diameter, balloon-to-artery ratio, stent-to-
esion-length ratio, creatinine clearance, ostial location,
rterial tortuosity, calcification, lesion length, baseline ref-
rence vessel diameter, and baseline minimal luminal diam-
ter. Epicardial vessel was forced into the equations. The
reslow-Day test for homogeneity was used to test for the
resence of specific interaction between randomization arm
nd epicardial vessel on clinical and angiographic outcome
ariables. All p values are two-sided.
ESULTS
f 1,314 patients enrolled in the TAXUS-IV trial, the
arget lesion was in the LAD in 536 patients (40.8%), in the
eft circumflex (LCX) in 364 patients (27.7%), and in the
ight coronary artery (RCA) in 414 patients (31.5%).
aseline features and procedural outcomes in the LAD
ubgroup. Of the 536 patients in the LAD subgroup, 264
atients were randomized to receive a paclitaxel-eluting
tent, and 272 patients to a bare-metal stent. Baseline
haracteristics were well matched between the two groups,
ith a non-significant trend toward larger reference vessel
iameter present in the paclitaxel-eluting stent group
Table 1). The number of stents implanted per patient,
ean stent length, diameter, and deployment parameters
ere similar between the paclitaxel and control stent groups
Table 2). Acute angiographic results were comparable
etween the two study cohorts.
linical and angiographic outcomes in the LAD sub-
roup. As shown in Table 3, death, myocardial infarction,
nd stent thrombosis rates occurred with similarly low
requency in the two treatment groups throughout the
ne-year follow-up period. Implantation of the paclitaxel-
luting stent compared to bare-metal stenting reduced the
ne-year rates of TLR and TVR by 69% and 62%, respec-
t
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Paclitaxel-Eluting Stent in LAD Stenoses April 19, 2005:1186–92ively, and the MACE rate by 61%. Of note, the need for
ypass graft surgery due to TVR was significantly reduced
mong patients randomized to the TAXUS stent.
Repeat catheterization was completed in 223 of 298
atients (75.3%) in the 9-month follow-up angiography
roup. Compared to bare-metal stenting, patients random-
zed to the paclitaxel-eluting stent had less late loss and a
ower loss index, resulting in greater luminal dimensions
nd a lower diameter stenosis at follow-up (Table 4).
ccordingly, the binary restenosis rate was reduced by 64%
ithin the stent, and by 58% in the analysis segment.
oreover, restenosis, when it did occur after paclitaxel-
luting stent placement, was significantly shorter in length
nd less frequently diffuse than restenosis after bare-metal
tent implantation.
utcomes of lesions in the proximal LAD location. The
arget lesion was located in the proximal LAD segment in
36 patients (44% of the overall LAD group); 126 were
ssigned to paclitaxel and 110 to bare-metal stent implan-
Table 1. Baseline Clinical and Angiographic C
Paclita
Age, yrs
Men
Diabetes mellitus requiring medication
Insulin use
Hypertension
Hyperlipidemia
Smoking, current
Prior myocardial infarction
Unstable angina
Left ventricular ejection fraction, %
Proximal LAD location
Lesion length, mm 1
Reference vessel diameter, mm
Minimal luminal diameter, mm
Diameter stenosis, %
LAD  left anterior descending coronary artery.
Table 2. Stent Implantation and Procedural R
Paclit
n stents per study lesion
Total stent length, mm
Maximum stent diameter, mm
Maximum device inflation pressure, atm
Maximum device diameter, mm
Balloon/artery ratio
Stent length/lesion length ratio (median) 1
Glycoprotein IIb/IIIa inhibitors used
Intravascular ultrasound used
Final reference vessel diameter, mm
Final minimal lumen diameter, mm
Analysis segment
In-stent
Final diameter stenosis, %
Analysis segment
In-stentLAD  left anterior descending coronary artery.ation. The results in the proximal LAD subgroup were, in
eneral, concordant to these observed in the overall LAD
ohort (Table 5).
elative outcomes in the LAD, LCX, and RCA. In
atients randomized to the bare-metal stent, the rates of
estenosis and adverse events during the follow-up period
ere similar after treatment of lesions in all three coronary
rteries. However, the likelihood of requiring bypass graft
urgery for TVR was significantly higher after bare-metal
tenting of the LAD than the RCA or LCX (Table 6). In
ontrast, though late loss tended to be slightly higher after
aclitaxel-eluting stent implantation in the LAD compared
o the RCA and LCX vessels, the one-year rates of TLR
nd TVR, including bypass graft surgery, were similar in all
hree coronary arteries after TAXUS stent implantation
Table 7).
By multivariate analysis, among patients with LAD
esions, randomization to the TAXUS stent was a signifi-
ant independent predictor of freedom from one-year TVR
cteristics of Patients With LAD Lesions
luting Stent
264)
Bare-Metal Stent
(n  272) p Value
12 61  11 0.56
2% 72.8% 0.77
2% 23.5% 0.54
8% 8.5% 0.70
2% 66.3% 0.24
4% 65.8% 0.21
3% 18.6% 0.20
1% 25.7% 0.92
5% 30.1% 0.31
10 56  10 0.71
7% 40.4% 0.31
5.74 13.33  620 0.64
0.39 2.64  0.44 0.06
0.32 0.94  0.30 0.77
10.6 64.3  10.1 0.13
of Patients With LAD Lesions
luting Stent
264)
Bare-Metal Stent
(n  272) p Value
 0.24 1.03  0.21 0.22
 7.51 20.79  6.85 0.31
 0.34 3.04  0.34 0.72
 2.77 15.01  3.17 0.09
 0.40 3.13  0.38 0.64
 0.15 1.20  0.16 0.04
.32–2.10) 1.59 (1.30–2.05) 0.55
.1% 56.7% 0.25
.0% 27.9% 0.84
 0.38 2.69  0.45 0.19
 0.43 2.14  0.49 0.13
 0.40 2.58  0.41 0.055
 9.9 20.8  11.2 0.39
 10.8 3.5  11.5 0.67hara
xel-E
(n 
62 
74.
21.
6.
61.
60.
23.
26.
34.
55 
47.
3.09 
2.71 
0.93 
65.7 esults
axel-E
(n 
1.05
21.43
3.05
14.57
3.15
1.17
.60 (1
62
27
2.74
2.20
2.65
20.0
3.0
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April 19, 2005:1186–92 Paclitaxel-Eluting Stent in LAD Stenoseshazard ratio [HR]  0.44 [95% confidence interval (CI)
.26 to 0.75], p  0.002) and analysis segment restenosis
odds ratio [OR]  0.42 [95% CI 0.20 to 0.89], p  0.02).
imilarly, among patients with stenoses in the LCX or
CA, randomization to the TAXUS stent was a significant
redictor of freedom from one-year TVR (HR 0.36 [95%
I 0.22 to 0.58], p  0.0001) and analysis segment
estenosis (OR  0.12 [95% CI 0.05 to 0.27], p  0.0001).
o significant interaction was present between randomiza-
ion arm and epicardial vessel (LAD vs. non-LAD) on
ither the rate of TVR at one year or analysis segment
estenosis (p  0.95 and 0.16, respectively).
Table 3. Clinical Outcomes After Stent Impla
Paclitaxe
St
(n 
30-day events
Major adverse cardiac events 3
1-year events
Cardiac death 1
Myocardial infarction 4
Target lesion revascularization 5
Percutaneous coronary intervention 4
Bypass graft surgery 1
Target vessel revascularization 8
Percutaneous coronary intervention 6
Bypass graft surgery 2
Target vessel failure 12
Major adverse cardiac events 13
CI  confidence interval; LAD  left anterior descending
Table 4. Angiographic Results at Nine-Month
Paclitaxel-E
(n 
Reference vessel diameter, mm 2.71 
Minimal lumen diameter, mm
Analysis segment 1.95 
In-stent 2.18 
Diameter stenosis, %
Analysis segment 28.2 
In-stent 19.3 
Binary restenosis
Analysis segment 11.
In-stent 8.
Acute gain
Analysis segment 1.24 
In-stent 1.67 
Late loss
Analysis segment 0.28 
In-stent 0.47 
Loss index
Analysis segment 0.21 
In-stent 0.29 
In-stent restenosis pattern
Focal 4.
Diffuse 2.
Proliferative 0.
Total occlusion 1.
In-stent restenosis length, mm 9.84 LAD  left anterior descending coronary artery.ISCUSSION
he present substudy of the TAXUS-IV trial demonstrates
hat the slow-release, polymer-based, paclitaxel-eluting
tent, when implanted in single de novo LAD lesions of
oderate complexity, markedly reduces recurrent clinical
vents and angiographic restenosis compared to use of an
dentical bare-metal stent. Moreover, when restenosis did
ccur with the TAXUS stent, the length of the restenotic
egment was shorter, and its pattern more focal. As a result,
andomization to the TAXUS stent rather than the bare-
etal stent significantly reduced the need for subsequent
n in LAD Lesions
ting Bare-Metal
Stent
(n  272)
Relative Risk
(95% CI) p Value
2.9% 1.16 (0.45–3.00) 0.76
1.1% 1.72 (0.41–7.18) 0.45
4.8% 0.96 (0.44–2.09) 0.91
16.7% 0.31 (0.17–0.56) 0.0001
12.6% 0.33 (0.17–0.66) 0.009
6.0% 0.19 (0.06–0.65) 0.003
18.9% 0.38 (0.23–0.65) 0.0002
14.4% 0.39 (0.22–0.71) 0.001
6.3% 0.35 (0.14–0.90) 0.02
20.5% 0.55 (0.36–0.86) 0.007
21.2% 0.59 (0.38–0.90) 0.01
ry artery.
ow-Up of Patients With LAD Lesions
Stent Bare-Metal Stent
(n  108) p Value
2.68  0.43 0.5887
1.63  0.60 0.0001
1.72  0.65 0.0001
39.6  19.1 0.0001
36.6  20.4 0.0001
26.9% 0.004
24.1% 0.002
1.21  0.50 0.56
1.64  0.45 0.68
0.54  0.57 0.0004
0.90  0.56 0.0001
0.46  0.50 0.0001
0.56  0.36 0.0001
9.3% 0.18
11.1% 0.01
2.8% 0.11
0.9% 1.00
13.70  7.00 0.08ntatio
l-Elu
ent
264)
.4%
.9%
.6%
.8%
.6%
.2%
.4%
.2%
.6%
.4%
.5%Foll
luting
115)
0.38
0.55
0.61
17.3
20.1
3%
7%
0.45
0.43
0.51
0.54
0.44
0.36
3%
6%
0%
7%
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Paclitaxel-Eluting Stent in LAD Stenoses April 19, 2005:1186–92ypass graft surgery, in addition to repeat PCI (21). More-
ver, use of the paclitaxel-eluting stent was safe, with
imilarly low rates of cardiac death and myocardial infarc-
ion over the one-year follow-up period after both
aclitaxel-eluting and bare stents in this important patient
ohort.
Some variability in the absolute and relative reductions in
he clinical and angiographic event rates after TAXUS
tenting was observed across the three major epicardial
Table 5. Results Among Randomized Patients
Paclitax
S
Clinical outcomes n 
30-day events
Major adverse cardiac events
1-year events
Cardiac death
Myocardial infarction
Target lesion revascularization
Target vessel revascularization
Percutaneous coronary intervention
Bypass graft surgery
Major adverse cardiac events 1
Angiographic results n
Reference vessel diameter, mm 2.81
Lesion length, mm 12.44
Binary restenosis
Analysis segment
In-stent
Late loss
Analysis segment 0.24
In-stent 0.40
CI  confidence interval; LAD  left anterior descending
Table 6. Comparative Results of Bare Metal S
Arteries
L
Baseline features n 
Diabetes mellitus 23
Reference vessel diameter, mm 2.64
Lesion length, mm 13.87
Clinical outcomes n 
30-day events
Major adverse cardiac events 2
1-year events
Target lesion revascularization 16
Target vessel revascularization 18
Percutaneous coronary intervention 14
Bypass graft surgery 6
Myocardial infarction 4
Cardiac death 1
Major adverse cardiac events 21
Angiographic results n 
Binary restenosis
Analysis segment 26
In-stent 24
Late loss
Analysis segment 0.54
In-stent 0.90*p  0.009 for comparison between the left anterior descending coro
LCX  left circumflex coronary artery.oronary arteries, possibly due to differences in vessel size,
esion length, and diabetes. Nonetheless, randomization to
he TAXUS stent was an independent determinate of
reedom from restenosis and TVR among both patients
ith LAD and non-LAD lesions. The fact that no specific
nteraction between randomization arm and epicardial ves-
el on either clinical or angiographic measures of restenosis
as identified suggests that the efficacy of the TAXUS stent
s independent of epicardial lesion location.
h Lesions in the Proximal LAD
uting Bare-Metal
Stent
Relative Risk
(95% CI) p Value
n  110
2.7% 1.45 (0.35–6.08) 0.6032
0.9% 2.63 (0.27–25.26) 0.38
5.5% 0.88 (0.28–2.72) 0.82
17.4% 0.32 (0.13–0.76) 0.0064
18.6% 0.36 (0.17–0.80) 0.009
14.0% 0.39 (0.16–0.95) 0.03
6.5% 0.24 (0.05–1.17) 0.055
22.1% 0.55 (0.29–1.04) 0.06
n  42
.36 2.80  0.41 — 0.97
.84 13.09  6.60 — 0.59
16.7% 0.44 (0.14–1.39) 0.20
16.7% 0.33 (0.09–1.19) 0.10
.53 0.54  0.66 — 0.01
.53 0.93  0.60 — 0.0001
ry artery.
Implantation Among the Three Coronary
RCA LCX p Value
n  209 n  171
24.4% 28.1% 0.55
44 2.96  0.50 2.67  0.46 0.0001
73 13.33  6.20 12.82  5.40 0.27
n  209 n  171
1.4% 2.9% 0.52
11.9% 16.6% 0.25
14.8% 17.2% 0.44
13.4% 13.7% 0.93
1.4%* 3.6% 0.026
3.5% 5.9% 0.50
0.5% 2.4% 0.26
17.7% 21.1% 0.46
n  90 n  69
20.0% 34.8% 0.11
20.0% 30.9% 0.29
57 0.67  0.56 0.66  0.58 0.25
56 0.90  0.58 0.99  0.59 0.50Wit
el-El
tent
126
4.0%
2.4%
4.8%
6.3%
7.9%
6.2%
1.6%
3.3%
 55
 0
 4
7.3%
5.5%
 0
 0tent
AD
272
.5%
 0.
 6.
272
.9%
.7%
.9%
.4%
.3%*
.8%
.1%
.2%
108
.9%
.1%
 0.
 0.nary artery (LAD) and right coronary artery (RCA) groups.
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April 19, 2005:1186–92 Paclitaxel-Eluting Stent in LAD StenosesThe one-year rates of TVR (8.4%) and MACE (13.5%)
bserved after paclitaxel-eluting stent placement in the
AD from the current study is similar to the reported 5% to
% TVR and up to 15% MACE rates at 6 to 12 months
fter surgical revascularization of the LAD (12,13,16,17).
mportantly, similar results were obtained with the TAXUS
tent after implantation in lesions located in the proximal
AD, a location that, in prior studies, has tended to benefit
rom bypass graft surgery rather than PCI (14,18). Again,
he results observed with the paclitaxel-eluting stent in the
resent analysis are very similar to that observed after
urgical revascularization of isolated proximal LAD lesions
n these earlier studies. The validity of this observation is
einforced by the similar clinical event rates in the bare-
etal stent arms of the TAXUS-IV trial and the previous
tent study (14), which, in turn, was more favorable than the
arlier study with balloon angioplasty of the proximal LAD
18).
Therefore, on the basis of the above findings, paclitaxel
tent implantation appears both safe and efficacious for
reatment of LAD stenoses, and may approach the efficacy
f surgical revascularization with a left internal mammary
rtery graft to the LAD. Of note, however, the enrollment
riteria in the current study limited the lesion types studied.
urthermore, whether contemporary PCI with drug-eluting
tents and optimal pharmacotherapy results in similar sur-
ival in diabetic patients as does bypass surgery is also
nknown (18). Prospective, randomized trials comparing
rug-eluting stents to bypass graft surgery are required to
roperly examine clinical outcomes after these two forms of
evascularization.
imitations and clinical perspectives. Although the
Table 7. Comparative Results of Paclitaxel-Elu
Coronary Arteries
L
Baseline features n 
Diabetes mellitus 21
Reference vessel diameter, mm 2.71
Lesion length, mm 13.09
Clinical outcomes n 
30-day events
Major adverse cardiac events 3
1-year events
Target lesion revascularization 5
Target vessel revascularization 8
Percutaneous coronary intervention 6
Bypass graft surgery 2
Myocardial infarction 4
Cardiac death 1
Major adverse cardiac events 13
Angiographic results n 
Binary restenosis
Analysis segment 11
In-stent 8
Late loss
Analysis segment 0.28
In-stent 0.47resent report represents a pre-specified analysis, subgroupnalyses inherently demonstrate selection bias and typically
ack adequate statistical power for robust comparisons
mong modest-sized cohorts. Ostial narrowings and bifur-
ation stenoses are examples of critical LAD lesions that
ere excluded from randomization. The results contained in
he present report also cannot be generalized to other
rug-eluting stent systems. Despite these caveats, the results
rom the present study demonstrate that, compared to
are-metal stents, the paclitaxel-eluting TAXUS stent sig-
ificantly enhances event-free survival in all three coronary
rteries. Longer-term follow-up data, further experience in
esions not enrolled in the TAXUS-IV trial, and direct
omparisons with bypass graft surgery are required to
ompletely characterize the relative benefits of this device in
atients with coronary atherosclerosis (23–25).
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